martes, 19 de octubre de 2021

Phase 2 trial shows COVID-19 recombinant protein vaccine elicits promising immunogenicity responses

Phase 2 trial shows COVID-19 recombinant protein vaccine elicits promising immunogenicity responses

No hay comentarios:

Publicar un comentario